Zelie Bailes

914 total citations · 1 hit paper
22 papers, 634 citations indexed

About

Zelie Bailes is a scholar working on Pulmonary and Respiratory Medicine, Physiology and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Zelie Bailes has authored 22 papers receiving a total of 634 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Pulmonary and Respiratory Medicine, 10 papers in Physiology and 5 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Zelie Bailes's work include Asthma and respiratory diseases (8 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers) and Inhalation and Respiratory Drug Delivery (6 papers). Zelie Bailes is often cited by papers focused on Asthma and respiratory diseases (8 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (7 papers) and Inhalation and Respiratory Drug Delivery (6 papers). Zelie Bailes collaborates with scholars based in United States, United Kingdom and Germany. Zelie Bailes's co-authors include Rozsa Schlenker‐Herceg, Vincent Cottin, Luca Richeldi, Kevin M. Brown, Roland M. du Bois, Toshio Kimura, Moisés Selman, Susanne Stowasser, Andrew Fowler and Guy Peachey and has published in prestigious journals such as CHEST Journal, Journal of Allergy and Clinical Immunology and The Lancet Respiratory Medicine.

In The Last Decade

Zelie Bailes

21 papers receiving 627 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials

2016 330 citations Luca Richeldi, Vincent Cottin et al. Respiratory Medicine profile →

Peers

Countries citing papers authored by Zelie Bailes

Since Specialization

Citations

This map shows the geographic impact of Zelie Bailes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zelie Bailes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zelie Bailes more than expected).

Fields of papers citing papers by Zelie Bailes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zelie Bailes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zelie Bailes. The network helps show where Zelie Bailes may publish in the future.

Co-authorship network of co-authors of Zelie Bailes

This figure shows the co-authorship network connecting the top 25 collaborators of Zelie Bailes. A scholar is included among the top collaborators of Zelie Bailes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zelie Bailes. Zelie Bailes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinic vs Home Spirometry for Monitoring Lung Function in Patients With Asthma 2023 ·CHEST Journal ·John Oppenheimer, Nicola A. Hanania, Rekha Chaudhuri, Hironori Sagara, Zelie Bailes, Andrew Fowler, Guy Peachey, Emílio Pizzichini, (unknown)	14
2	A Comparison of Clinic Versus Home Spirometry in the CAPTAIN Study 2021 ·F Gardiner, Emílio Pizzichini, Zelie Bailes, Guy Peachey, (unknown), Rekha Chaudhuri, John Oppenheimer, Nicola A. Hanania, (unknown), Andrew Fowler, N. Barnes	2
3	Measuring respiratory symptoms in moderate/severe asthma: evaluation of a respiratory symptom tool, the E-RS®: COPD in asthma populations 2021 ·Journal of Patient-Reported Outcomes ·Maggie Tabberer, Robyn von Maltzahn, Elizabeth D. Bacci, (unknown), (unknown), (unknown), Zelie Bailes, Andrew Fowler, (unknown), Lindsey Murray	7
4	Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial 2020 ·The Lancet Respiratory Medicine ·Laurie A. Lee, Zelie Bailes, Neil Barnes, Louis‐Philippe Boulet, (unknown), Andrew Fowler, Nicola A. Hanania, Huib A.M. Kerstjens, Edward Kerwin, Robert A. Nathan, John Oppenheimer, Alberto Papi, Steven Pascoe, Guy Brusselle, Guy Peachey, Neal Sule, Maggie Tabberer, Ian Pavord	150
5	A phase IIb, randomised, parallel-group study: the efficacy, safety and tolerability of once-daily umeclidinium in patients with asthma receiving inhaled corticosteroids 2020 ·Respiratory Research ·Edward Kerwin, Steven Pascoe, Zelie Bailes, Robert A. Nathan, David I. Bernstein, Ronald Dahl, Robyn von Maltzahn, K. Thomas Robbins, Andrew Fowler, (unknown)	10
6	Captain Study: Evaluating the Efficacy of Once-Daily, Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Versus FF/VI in Inadequately Controlled Asthma Using Change in Asthma Control Questionnaire and the Relationship with Trough FEV ₁ 2020 ·Andrew Fowler, Huib A.M. Kerstjens, Zelie Bailes, Maggie Tabberer, (unknown), Guy Peachey, John Oppenheimer, (unknown)	3
7	Evaluation of the Psychometric Properties, Scoring Algorithm, and Score Interpretation of the E-RS®: Asthma in Two Clinical Trials of Moderate to Severe Asthma 2020 ·(unknown), Robyn von Maltzahn, Elizabeth D. Bacci, (unknown), (unknown), Zelie Bailes, Andrew Fowler, (unknown), Louise Murray	1
8	CAPTAIN: Effects of age on response to triple therapy in patients with inadequately controlled asthma on ICS/LABA 2020 ·Louis‐Philippe Boulet, (unknown), Huib A.M. Kerstjens, Alberto Papi, (unknown), Ian Pavord, Zelie Bailes, Guy Brusselle, Neil Barnes, Nicola A. Hanania, Steven Pascoe, John Oppenheimer, Emílio Pizzichini, Andrew Fowler	0
9	Analytical Comparison of Continuous Subcutaneous Insulin Infusion and Multiple Daily Injections in Children and Adolescents with Type I Diabetes Mellitus 2020 ·(unknown), (unknown), (unknown), (unknown), Zelie Bailes, (unknown), (unknown), Deepak Kumar Singh, (unknown)	1
10	Once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) versus FF/VI in inadequately controlled asthma: the CAPTAIN study 2020 ·Journal of Allergy and Clinical Immunology ·Ian Pavord, Guy Peachey, Huib A.M. Kerstjens, Edward Kerwin, Robert A. Nathan, Nicola A. Hanania, Steven Pascoe, Andrew Fowler, Zelie Bailes, (unknown), Neal Sule, Neil Barnes, Louis‐Philippe Boulet, Maggie Tabberer, (unknown)	1
11	Oral glucose lowering with linagliptin and metformin compared with linagliptin alone as initial treatment in Asian patients with newly diagnosed type 2 diabetes and marked hyperglycemia: Subgroup analysis of a randomized clinical trial 2017 ·Journal of Diabetes Investigation ·Ronald C.W., Stefano Del Prato, Baptist Gallwitz, Vyankatesh Shivane, Diane J. Lewis-D’Agostino, Zelie Bailes, Sanjay Patel, Jisoo Lee, Maximilian von Eynatten, (unknown), Stuart A. Ross	11
12	Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS® trials breakdown → 2016 ·Respiratory Medicine ·Luca Richeldi, Vincent Cottin, Roland M. du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker‐Herceg, Susanne Stowasser, Kevin M. Brown	330
13	Effect of anti-acid medication on reduction in FVC decline with nintedanib 2016 ·Pneumologie ·Ulrich Costabel, Bruno Crestani, Zelie Bailes, Rozsa Schlenker‐Herceg, Ganesh Raghu	2
14	Linagliptin plus metformin in patients with newly diagnosed type 2 diabetes and marked hyperglycemia 2016 ·Postgraduate Medicine ·Stuart A. Ross, A. Enrique Caballero, Stefano Del Prato, Baptist Gallwitz, Diane J. Lewis-D’Agostino, Zelie Bailes, Sandra Thiemann, Sanjay Patel, Hans‐Juergen Woerle, Maximilian von Eynatten	5
15	Subgroup analysis of Asian patients in the INPULSIS^® trials of nintedanib in idiopathic pulmonary fibrosis 2016 ·Respirology ·Hiroyuki Taniguchi, Zuojun Xu, Arata Azuma, Yoshikazu Inoue, Huiping Li, Tsuyoshi Fujimoto, Zelie Bailes, Rozsa Schlenker‐Herceg, Dong S. Kim	31
16	Efficacy and Safety of Linagliptin Co-Administered with Low-Dose Metformin Once Daily Versus High-Dose Metformin Twice Daily in Treatment-Naïve Patients with Type 2 Diabetes: a Double-Blind Randomized Trial 2015 ·Advances in Therapy ·Linong Ji, Bernard Zinman, Sanjay Patel, (unknown), Zelie Bailes, Sandra Thiemann, Thomas Seck	13
17	Effect of anti-acid medication on reduction in FVC decline with nintedanib 2015 ·Ganesh Raghu, Bruno Crestani, Zelie Bailes, Rozsa Schlenker‐Herceg, Ulrich Costabel	16
18	Efficacy and Safety of Nintedanib in US and Non-US Patients With Idiopathic Pulmonary Fibrosis (IPF) in the INPULSIS Trials 2015 ·CHEST Journal ·(unknown), Mitchell Kaye, Zelie Bailes, Dirk Eßer, Craig Conoscenti, Kevin R. Flaherty	2
19	Effect of baseline emphysema on reduction in FVC decline with nintedanib in the INPULSIS™ trials 2015 ·Pneumologie ·Marija Pfeifer, Vincent Cottin, H. Taniguchi, Luca Richeldi, (unknown), Mitchell Kaye, D.M. Hansell, Zelie Bailes, Rozsa Schlenker‐Herceg, Ganesh Raghu	11
20	Initial combination of linagliptin and metformin compared with linagliptin monotherapy in patients with newly diagnosed type 2 diabetes and marked hyperglycaemia: a randomized, double‐blind, active‐controlled, parallel group, multinational clinical trial 2014 ·Diabetes Obesity and Metabolism ·S. Ross, A. Enrique Caballero, Stefano Del Prato, Baptist Gallwitz, Diane J. Lewis-D’Agostino, Zelie Bailes, Sandra Thiemann, S. Patel, Hans J. Woerle, Maximilian von Eynatten	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact